233 related articles for article (PubMed ID: 34851173)
1. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
3. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
[TBL] [Abstract][Full Text] [Related]
7. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
9. Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.
Burke JM; Yu KS; Mordi U; Bloudek B; Liu N; Phillips T
J Manag Care Spec Pharm; 2023 Mar; 29(3):314-323. PubMed ID: 36840956
[No Abstract] [Full Text] [Related]
10. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
Ngu HS; Savage KJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
12. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
Ngu HS; Savage KJ
Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Camus V; Thieblemont C; Gaulard P; Cheminant M; Casasnovas RO; Ysebaert L; Damaj GL; Guidez S; Pica GM; Kim WS; Lim ST; Andre M; Gutiérrez N; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Tucci A; Fogarty P; Farhat H; Abraham J; Abarah W; Belmecheri F; Ribrag V; Delfau-Larue MH; Cottereau AS; Itti E; Li J; Delarue R; de Leval L; Morschhauser F; Bachy E
J Clin Oncol; 2024 May; 42(14):1612-1618. PubMed ID: 38364196
[No Abstract] [Full Text] [Related]
15. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK; Gong JZ; Porcu P
Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
18. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
[TBL] [Abstract][Full Text] [Related]
20. ECHELON-2 - brentuximab raises PTCL outcomes to new levels.
Killock D
Nat Rev Clin Oncol; 2019 Mar; 16(3):145. PubMed ID: 30602757
[No Abstract] [Full Text] [Related]
[Next] [New Search]